Here are the 10-Q quarterly reports from Heartbeam, Inc. Warrant (BEATW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BEATW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEATW filings page.
HeartBeam, Inc. reported no revenue for the quarter and six months ended June 30, 2026 and continues to operate at a loss while developing its ambulatory cardiac monitoring platform. Net loss was $5.0 million for the quarter and $9.7 million for the first half of 2026.
Cash and cash equivalents were $8.7 million as of June 30, 2026, up from $4.4 million at year-end, primarily from an underwritten equity offering that generated $11.5 million in gross proceeds (about $10.3 million net) plus at-the-market sales. Operating cash outflow was $7.0 million in the first half.
The company discloses that existing liquidity is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. It received FDA clearances in December 2024 and December 2025 for its 3D ECG telehealth products, is running pilot and ALIGN-ACS studies, and is pursuing a shift toward licensing its 3D ECG signal technology and limited commercial launches. During the quarter HeartBeam also recorded CEO and director departures and received a Nasdaq minimum bid-price deficiency notice with a compliance period through December 29, 2026.
HeartBeam, Inc. reported another quarter of losses with no revenue and highlighted serious liquidity concerns. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.7 million, narrower than the $5.5 million loss a year earlier. Operating expenses were $4.7 million, with selling, general and administrative costs rising 17% and research and development falling 32% as product development and consulting spending declined.
Cash and cash equivalents were $2.0 million as of March 31, 2026, and management stated this is insufficient to fund operations for the next twelve months, raising “substantial doubt” about the company’s ability to continue as a going concern. Subsequent to quarter-end, HeartBeam completed an underwritten offering of 14,375,000 shares of common stock for gross proceeds of approximately $11.5 million. The company remains pre-revenue despite FDA clearances for its 3D ECG telehealth system and is beginning a limited commercial launch and multiple pilot studies, while expecting no material commercial revenue in 2026.